Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Supplier: Comprehensive Analysis Of Sourcing, Manufacturing, And Quality Standards For Pharmaceutical And Nutraceutical Applications

NOV 17, 202655 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine phosphate (phosphocreatine, PCr) serves as a critical high-energy phosphate reservoir in mammalian tissues, particularly in skeletal and cardiac muscle, where it facilitates rapid ATP regeneration during periods of intense metabolic demand. As a pharmaceutical intermediate and active ingredient in cardioprotective and neuroprotective therapies, the selection of a reliable Creatine Phosphate Supplier is paramount for R&D teams developing formulations with stringent purity, stability, and bioavailability requirements. This article provides an in-depth examination of supplier evaluation criteria, synthetic routes, quality control methodologies, regulatory compliance, and emerging applications to guide expert-level sourcing decisions.
Want to know more material grades? Try Patsnap Eureka Material.

Chemical Identity And Structural Characteristics Of Creatine Phosphate For Supplier Evaluation

Creatine phosphate (N-phosphorylcreatine, CAS 67-07-2) is the phosphorylated derivative of creatine (N-methyl-N-guanylglycine), bearing a high-energy phosphate bond at the guanidino nitrogen. Its molecular formula is C₄H₁₀N₃O₅P, with a molecular weight of approximately 211.11 g/mol (anhydrous form). The compound exists predominantly as disodium or tetrasodium salts in pharmaceutical formulations to enhance aqueous solubility and stability 1. The reversible enzymatic reaction catalyzed by creatine kinase (CK) is central to cellular bioenergetics: PCr + ADP + H⁺ ⇌ ATP + Cr. This reaction maintains high ATP/ADP ratios in tissues with fluctuating energy demands, such as myocardium, brain, and skeletal muscle 2. When evaluating a Creatine Phosphate Supplier, understanding the salt form (e.g., disodium tetrahydrate vs. anhydrous disodium) is critical, as hydration state directly impacts molecular weight, hygroscopicity, and dosing accuracy 4.

Key physicochemical properties relevant to supplier specifications include:

  • Solubility: Disodium creatine phosphate exhibits high aqueous solubility (>100 mg/mL at 25°C), facilitating parenteral and oral liquid formulations 13.
  • Stability: The compound is prone to hydrolytic degradation to creatine and inorganic phosphate, particularly under acidic conditions (pH <6) and elevated temperatures (>40°C). Stability studies indicate <5% degradation over 6 months at pH 7.2–7.8 and 25°C when buffered appropriately 13.
  • Hygroscopicity: Hydrated salts (e.g., tetrahydrate) require controlled humidity storage (<60% RH) to prevent caking and loss of crystallinity 4.
  • Purity: Pharmaceutical-grade material should contain ≥98.0% creatine phosphate (anhydrous basis), with creatine and creatinine impurities each <1.0%, and inorganic phosphate <0.5% 89.

Suppliers must provide Certificates of Analysis (CoA) documenting these parameters via validated HPLC-ELSD or HPLC-UV methods (see Quality Control section) 89.

Synthetic Routes And Manufacturing Processes: Implications For Supplier Selection

The choice of synthetic route profoundly influences product purity, cost, and environmental footprint. Two primary methods dominate industrial production:

Chemical Phosphorylation With Phosphorus Oxychloride (POCl₃)

This classical approach, first reported by Zeile and Fawaz (1938) and refined by Ennor and Stocken (1948), involves direct phosphorylation of creatine in strongly alkaline media (pH >12) using POCl₃ 511. The reaction proceeds via formation of dichlorophosphoric acid creatinine intermediate, followed by hydrolysis and neutralization with NaOH to yield disodium creatine phosphate 10. Key process parameters include:

  • Stoichiometry: Creatine:POCl₃ molar ratio of 1:1.1–1.2 to minimize unreacted creatine 10.
  • Temperature control: Reaction conducted at 0–5°C to suppress side reactions (e.g., creatinine formation) 10.
  • Solvent system: Dichloromethane or acetonitrile used to solubilize creatine and control exotherm 10.
  • Purification: Residual POCl₃ removed by toluene extraction; product crystallized from ethanol/water (95:5 v/v) 10.

Advantages: High yield (60–75% based on creatine); scalable to multi-kilogram batches 10.

Disadvantages: Use of hazardous POCl₃ (corrosive, moisture-sensitive) necessitates specialized equipment and waste treatment; residual phosphate impurities (0.3–0.8%) require ion-exchange chromatography for pharmaceutical-grade material 610.

Recent innovations include continuous-flow microreactor synthesis, which reduces POCl₃ residence time and improves safety while achieving >70% yield and <0.2% phosphate residue 10.

Enzymatic Phosphorylation With 3-Phosphoglyceric Acid (3-PGA)

This biocatalytic route, developed by Beaucamp (1972), employs aqueous muscle extract containing creatine kinase, phosphoglycerate kinase, and glyceraldehyde-3-phosphate dehydrogenase to transfer phosphate from 3-PGA to creatine in the presence of catalytic ATP 5. The process operates at pH 8.5–9.0 and 25–37°C, followed by brief heating (70–100°C, 5–10 min) to denature enzymes and facilitate product recovery 5.

Advantages: Mild conditions; no toxic reagents; high stereochemical purity; suitable for GMP-compliant facilities 5.

Disadvantages: Lower volumetric productivity (10–20 g/L vs. 50–100 g/L for chemical route); enzyme cost (~$500/kg 3-PGA vs. $50/kg POCl₃); requires cold-chain logistics for enzyme stability 5.

Suppliers utilizing enzymatic synthesis typically target high-value applications (e.g., injectable cardioprotectants) where purity and regulatory acceptance justify premium pricing 5.

Purification And Salt Form Conversion

Regardless of synthetic route, crude creatine phosphate undergoes purification via:

  1. Ion-exchange chromatography: Anionic resin (e.g., Dowex 1×8, Cl⁻ form) elutes creatine (0.02–0.15 M NaCl) separately from creatine phosphate (0.2–0.8 M NaCl), achieving >99.5% purity 6.
  2. Crystallization: Disodium salt precipitated from ethanol/water at 4°C; recrystallization from 95% ethanol yields pharmaceutical-grade material 610.
  3. Lyophilization: Aqueous solutions freeze-dried to anhydrous or defined hydrate forms (e.g., tetrahydrate) 4.

Suppliers should disclose purification protocols and provide impurity profiles (HPLC chromatograms) to verify absence of genotoxic impurities (e.g., POCl₃ hydrolysis products) 89.

Quality Control Methodologies And Analytical Standards For Creatine Phosphate Suppliers

Robust analytical methods are essential for supplier qualification and batch release. Regulatory agencies (FDA, EMA, NMPA) mandate validated assays per ICH Q2(R1) guidelines.

High-Performance Liquid Chromatography (HPLC) Methods

HPLC-ELSD (Evaporative Light Scattering Detection): Preferred for simultaneous quantitation of creatine phosphate, creatine, creatinine, and inorganic phosphate 8. Typical conditions:

  • Column: C₁₈ reversed-phase (250 mm × 4.6 mm, 5 μm) 8.
  • Mobile phase: Gradient of 0.02 M potassium dihydrogen phosphate (pH 6.5) and acetonitrile 8.
  • Flow rate: 1.0 mL/min; injection volume 20 μL 8.
  • Detection: ELSD at 50°C, nitrogen flow 2.5 L/min 8.
  • Quantitation: External standard method; LOQ 0.05% for impurities 8.

HPLC-UV: Alternative method using UV detection at 210 nm for creatine phosphate (ε = 1,200 M⁻¹cm⁻¹) and 234 nm for creatinine 9. Advantages include lower equipment cost; disadvantages include interference from UV-absorbing excipients 9.

Stability-Indicating Assays

Suppliers must demonstrate stability via forced degradation studies (acid, base, oxidative, thermal, photolytic stress per ICH Q1A/Q1B) 9. Validated methods should resolve degradation products (e.g., creatine, creatinine, cyclic creatine phosphate) with resolution >2.0 9. Acceptance criteria: ≥95.0% assay after 6 months at 25°C/60% RH (Zone II) or 3 months at 40°C/75% RH (accelerated) 9.

Residual Solvent And Heavy Metal Analysis

  • Residual solvents: GC-FID per USP <467> (ethanol <5,000 ppm, dichloromethane <600 ppm, toluene <890 ppm) 10.
  • Heavy metals: ICP-MS per USP <233> (Pb <5 ppm, As <2 ppm, Cd <1 ppm, Hg <3 ppm) 4.
  • Microbial limits: Total aerobic count <10³ CFU/g, yeast/mold <10² CFU/g, absence of E. coli and Salmonella per USP <61>/<62> 4.

Suppliers should provide multi-batch CoAs (n ≥3) demonstrating consistent compliance with these specifications.

Regulatory Compliance And Documentation Requirements For Pharmaceutical-Grade Creatine Phosphate

Sourcing from GMP-certified suppliers is non-negotiable for pharmaceutical applications. Key regulatory considerations include:

Drug Master File (DMF) And Certificate Of Suitability (CEP)

Suppliers should hold an active Type II DMF (US FDA) or CEP (EDQM) for creatine phosphate disodium, documenting manufacturing site, process validation, impurity control strategy, and stability data 4. DMF holders must update filings within 30 days of process changes 4.

ICH Q7 GMP Compliance

Facilities must demonstrate:

  • Process validation: Three consecutive conforming batches at commercial scale 4.
  • Change control: Risk-based assessment (ICH Q9) for raw material substitutions, equipment modifications, or site transfers 4.
  • Traceability: Batch genealogy linking API to starting materials (creatine, POCl₃ or 3-PGA) 4.

Pharmacopeial Monographs

While creatine phosphate lacks a USP monograph, suppliers may reference:

  • Chinese Pharmacopoeia (ChP 2020): Monograph for Sodium Creatine Phosphate for Injection (assay 95.0–105.0%, pH 7.0–9.0, sterility, bacterial endotoxins <0.5 EU/mg) 4.
  • European Pharmacopoeia (Ph. Eur. 10.0): General chapter 2.2.29 (Liquid Chromatography) applicable to HPLC methods 8.

Suppliers targeting EU markets should align specifications with Ph. Eur. requirements for related substances (individual impurity <0.5%, total <2.0%) 8.

Applications Of Creatine Phosphate: Matching Supplier Capabilities To End-Use Requirements

Cardiovascular Therapeutics

Creatine phosphate is approved in >30 countries (China, Russia, Italy, Japan) as an injectable cardioprotectant for acute myocardial infarction, heart failure, and cardiac surgery 23. Mechanism: PCr donates phosphate to ADP in ischemic myocardium, sustaining ATP levels and reducing infarct size 2. Clinical dosing: 1–2 g IV bolus followed by 1 g q12h for 5–7 days 2.

Supplier requirements: Sterile, pyrogen-free API (<0.5 EU/mg); particle size <50 μm for lyophilized vials; stability ≥24 months at 2–8°C 4. Suppliers must provide stability data in final formulation (e.g., 1 g/10 mL in 0.9% NaCl) demonstrating <5% degradation over 48 h at 25°C 13.

Neuroprotection And Neurodegenerative Diseases

Preclinical studies demonstrate PCr efficacy in Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) models, attributed to enhanced mitochondrial function and reduced oxidative stress 17. Oral bioavailability is limited (<10%) due to intestinal hydrolysis; prodrug strategies (e.g., salicyl alcohol esters, cyclocreatine phosphate) improve membrane permeability 1516.

Supplier requirements: Research-grade PCr (≥95% purity) for in vitro studies; GMP-grade for IND-enabling toxicology; prodrug synthesis capabilities (esterification, salt formation) 1516.

Sports Nutrition And Ergogenic Supplements

Creatine phosphate supplements (typically as disodium salt) are marketed for ATP replenishment during high-intensity exercise 112. Enteric-coated formulations bypass gastric degradation, enhancing bioavailability vs. creatine monohydrate 12.

Supplier requirements: Food-grade PCr (≥98% purity, compliant with FDA GRAS or EU Novel Foods Regulation); kosher/halal certification; non-GMO documentation 112. Stability in acidic beverages (pH 3.0–4.5) is critical; formulations with tribasic potassium phosphate buffer (pH 7.2–7.8) maintain >90% PCr over 6 months at 25°C 1319.

Emerging Applications: Tissue Preservation And Regenerative Medicine

Creatine phosphate supplementation of organ preservation solutions (e.g., University of Wisconsin solution) improves post-transplant graft function by maintaining ATP during cold ischemia 2. Dosing: 5–10 mM PCr in preservation medium 2.

Supplier requirements: Ultra-pure PCr (≥99.5%, endotoxin <0.1 EU/mg); compatibility with hypothermic storage (4°C, 48–72 h); sterile filtration (0.22 μm) 2.

Supplier Qualification Framework: A Risk-Based Approach For R&D Procurement

Selecting a Creatine Phosphate Supplier requires systematic evaluation across technical, regulatory, and commercial dimensions. Recommended qualification workflow:

Stage 1: Desktop Assessment

  • Regulatory status: Verify DMF/CEP, GMP certificates (ISO 9001, ISO 13485 for medical devices), and FDA inspection history (Form 483 observations) 4.
  • Technical capability: Review synthetic route, purification methods, and analytical portfolio (HPLC, GC, ICP-MS) 568.
  • Supply chain transparency: Request supplier questionnaire documenting raw material sources (creatine origin, POCl₃ manufacturer), subcontractors, and business continuity plans 4.

Stage 2: Sample Evaluation

  • Analytical testing: Independent verification of CoA claims (assay, impurities, residual solvents, heavy metals) using orthogonal methods 89.
  • Stability assessment: Accelerated stability (40°C/75% RH, 3 months) in intended formulation matrix 9.
  • Functional testing: Enzymatic activity assay (CK
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
BOEHRINGER MANNHEIM GMBH.Pharmaceutical-grade creatine phosphate manufacturing for injectable cardioprotectants and research applications requiring high purity and GMP compliance.Enzymatic Creatine Phosphate Production SystemEnzymatic phosphorylation using 3-phosphoglyceric acid and muscle extract achieves excellent yields without toxic reagents like phosphorus oxychloride, enabling simple and economically feasible large-scale production.
SHANGHAI HUATUO MEDICAL SCIENCE CO. LTD.Quality control and batch release testing for creatine phosphate disodium salt intermediates and finished pharmaceutical products in GMP-certified facilities.HPLC-ELSD Quality Control MethodHigh-performance liquid chromatography with evaporative light scattering detection enables simultaneous quantitation of creatine phosphate, creatine, creatinine, and inorganic phosphate with LOQ of 0.05% for impurities, ensuring pharmaceutical-grade purity ≥98%.
XENOPORT INC.Treatment of ischemia, heart failure, neurodegenerative diseases (Huntington's, Parkinson's, ALS), and tissue preservation for organ transplantation requiring enhanced cellular ATP levels.Membrane Permeable Creatine Phosphate ProdrugsSalicyl alcohol ester and cyclocreatine phosphate prodrugs improve membrane permeability and oral bioavailability (>10-fold vs. native creatine phosphate), enhancing therapeutic efficacy in energy metabolism disorders.
HARBIN BOLAI PHARMACEUTICAL CO. LTD.Oral solid dosage forms for cardiovascular therapeutics, sports nutrition, and muscle performance enhancement where injectable routes are impractical or patient compliance is challenging.Enteric-Coated Oral Creatine Phosphate FormulationEnteric coating with acrylic resin II protects creatine phosphate sodium from gastric degradation, achieving >90% stability over 6 months and enabling oral administration for cardiac and skeletal muscle protection.
THE COCA-COLA COMPANYSports nutrition and ergogenic supplement beverages for ATP replenishment during high-intensity exercise, providing convenient alternative to powdered creatine monohydrate supplements.Stable Ready-to-Drink Creatine BeverageBuffering system with tribasic potassium phosphate maintains pH 7.2-7.8, achieving <5% creatine degradation over 6 months at 25°C and enabling shelf-stable liquid creatine supplementation.
Reference
  • Creatine supplement
    PatentInactiveUS5773473A
    View detail
  • Method of increasing creatine supply depot
    PatentInactiveUS5767159A
    View detail
  • Method of increasing creatine supply depot
    PatentInactiveFI950302A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png